Rentschler Biopharma and Leukocare reported about effective cooperation

| By | CDMO, Contract Manufacturing, Drug Development

Rentschler Biopharma SE (Laupheim, Germany), a leading contract development and manufacturing organization (CDMO), and Leukocare AG (Martinsried, Germany), a biotechnology company, reported on the successful first year of their unique strategic alliance. The collaboration incorporates best-in-class formulation development in every step of the biopharmaceutical development and manufacturing process.

The benefits of this combination include competitive advantages, shorter development timelines, cost savings and extra patent protection for client products. The entire manufacturing process can be made more effective. In the past year, the alliance has won several new client projects, including four with US-based companies.

Dr. Frank Mathias, CEO of Rentschler Biopharma SE, commented: “The first year of this strategic alliance between Rentschler Biopharma and Leukocare was a great success and has proven our rationale to deliver best-in-class formulation throughout the biopharmaceutical value chain. By repositioning formulation as a key success factor in biopharmaceutical development, we have initiated vital discussions throughout the industry. Both existing and new clients have responded very positively to this new strategy.”

Leukocare is the specialized technology partner and the exclusive formulation developer for Rentschler Biopharma’s biopharmaceutical development business. Rentschler Biopharma is the first and only CDMO to have access to Leukocare’s patented SPS® formulation technologies.